Bracco Imaging is now advancing to prospective, controlled, large-scale Phase 3 studies aimed at evaluating the safety and efficacy of BR55 when used not only to detect angiogenesis but also active inflammation in patients with Crohn's disease.
"Today's milestone is a result of our deep commitment to innovation that advances precision imaging technologies," said Fulvio Renoldi Bracco, CEO, Bracco Imaging Group. "As a leader in diagnostic imaging, Bracco will continue to invest in promising approaches, such as the science of microbubble technology, which enhances the contrast in ultrasound and shows great potential for additional targeted applications."
Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About BR55
BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection is an investigational ultrasound contrast agent designed to bind to VEGFR2, a protein that plays a central role in angiogenesis and inflammatory processes. By targeting VEGFR2, BR55 enables real-time, non-invasive imaging of areas of angiogenesis, offering the potential for earlier and more accurate assessment of active inflammation in conditions like Crohn's disease. This precision imaging approach may significantly enhance clinicians' ability to diagnose and monitor disease activity, guiding better treatment decisions.
About Bracco Imaging
Bracco Imaging is a global leader in diagnostic imaging, providing advanced imaging agents and state-of-the-art delivery systems across a wide range of modalities, including X-ray, MRI, Nuclear Medicine, and Ultrasound. With a legacy of innovation and a commitment to improving patient outcomes, Bracco continues to pioneer technologies that enhance diagnostic accuracy and transform patient care.
Back to HCB News
